Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

Saad Z Usmani, Carlyn R Tan, Sydney X Lu, Dhwani Patel, Benjamin Diamond, Gunjan Shah, Michael Scordo, Oscar Lahoud, David J Chung, Heather Landau, Hani Hassoun, Sergio Giralt, Ying Taur, C Ola Landgren, Gladys Block, Torin Block, Jonathan U Peled, Marcel R M van den Brink, Alexander M Lesokhin, Tala Shekarkhand, Kylee H Maclachlan, Andriy Derkach, Meghan Salcedo, Kelly Barnett, Julia Caple, Jenna Blaslov, Linh Tran, Amanda Ciardiello, Miranda Burge, Urvi A Shah, Peter Adintori, Justin Cross, Matthew J Pianko, Kinga Hosszu, Devin McAvoy, Sham Mailankody, Neha Korde, Malin Hultcrantz

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 2022;28(23):5149-5155

PMID: 36170461

Abstract

PURPOSE

Sustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome is affected by diet, and in turn can modulate host immunity, for example through production of short-chain fatty acids including butyrate. We hypothesized that dietary factors affect the microbiome (abundance of butyrate-producing bacteria or stool butyrate concentration) and may be associated with multiple myeloma outcomes.

EXPERIMENTAL DESIGN

We examined the relationship of dietary factors (via a food frequency questionnaire), stool metabolites (via gas chromatography-mass spectrometry), and the stool microbiome (via 16S sequencing - α-diversity and relative abundance of butyrate-producing bacteria) with sustained MRD negativity (via flow cytometry at two timepoints 1 year apart) in myeloma patients on lenalidomide maintenance. The Healthy Eating Index 2015 score and flavonoid nutrient values were calculated from the food frequency questionnaire. The Wilcoxon rank sum test was used to evaluate associations with two-sided P < 0.05 considered significant.

RESULTS

At 3 months, higher stool butyrate concentration (P = 0.037), butyrate producers (P = 0.025), and α-diversity (P = 0.0035) were associated with sustained MRD negativity. Healthier dietary proteins, (from seafood and plants), correlated with butyrate at 3 months (P = 0.009) and sustained MRD negativity (P = 0.05). Consumption of dietary flavonoids, plant nutrients with antioxidant effects, correlated with stool butyrate concentration (anthocyanidins P = 0.01, flavones P = 0.01, and flavanols P = 0.02).

CONCLUSIONS

This is the first study to demonstrate an association between a plant-based dietary pattern, stool butyrate production, and sustained MRD negativity in multiple myeloma, providing rationale to evaluate a prospective dietary intervention.

©2022 American Association for Cancer Research.

Address: Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Donald B. and Catherine C. Marron Cancer Metabolism Center, Sloan Kettering Institute, New York, New York.; Department of Medicine, University of Michigan, Ann Arbor, Michigan.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Palo Alto, California.; Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida.; Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; NutritionQuest, Berkeley, California.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.